On this page

VerafloxTM

Pradofloxacin

Veterinary NADA Approved 620 adverse event reports

Overview

Source: Animal Drugs @ FDA
Proprietary name
VerafloxTM
Active ingredient
Pradofloxacin
Application type
NADA
Sponsor
Elanco US Inc.
Applications on record
1
First published
April 1, 2021

Adverse event reports

Source: openFDA VeDDRA
620
Reports mentioning this ingredient
February 18, 2013 – March 13, 2026
353
Classified serious
per reporter assessment
34
Lack of expected efficacy
resistance signal
1
Human operator exposure
needle-stick or splash
Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “PRADOFLOXACIN”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term) Reports Relative frequency
Behavioural disorder NOS 63
Vomiting 56
Hypersalivation 50
Diarrhoea 47
Lethargy (see also Central nervous system depression in 'Neurological') 42
Anorexia 41
Uncoded sign 35
Death 31
Death by euthanasia 30
Other abnormal test result NOS 28
Blindness 27
UNPALATABLE 27
Weight loss 26
Ataxia 20
Vocalisation 18
Lack of efficacy - NOS 18
Elevated blood urea nitrogen (BUN) 16
Hiding 16
Foaming at the mouth 15
Emesis (multiple) 15

Species affected

Source: openFDA VeDDRA
Cat 506 Dog 13 Human 3 Cattle 2 Fallow 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA FDA CVM Applications, sponsor, status, withdrawal
Animal & Veterinary Events FDA CVM VeDDRA adverse event aggregates by active ingredient